1. Stocks
    2. /
  2. Respiri Ltd (ASX: RSH)
    3. /

Respiri Ltd (ASX: RSH) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Respiri Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $41.20 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 722.84 million
Earnings per share -0.020
Dividend per share N/A
Year To Date Return -54.62%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

See The 5 Stocks

*Returns as of August 16th 2021

Respiri Ltd (ASX: RSH)
Latest News

RSH ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Respiri Ltd

Respiri Ltd is a company engaged in research, development, and commercialization of medical devices and the production of mobile health applications for the management of asthma and related chronic respiratory diseases. It operates throughthe following segments: The Australia segment includes research, development, and commercialization of medical devices and the production of mobile health applications in Australia. The Israel segment refers to the research, development and, commercialization of medical devices, and the production of mobile health applications in Israel. It's acoustic respiratory monitoring (ARM) technology records airway sounds to detect continuous adventitious breath sounds (CABS) and measures the extent of wheezing caused by airway obstruction.

RSH Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
01 Dec 2021 $0.06 $0.00 0.00% 59,744 $0.06 $0.06 $0.06
30 Nov 2021 $0.06 $0.00 0.00% 126,716 $0.06 $0.06 $0.06
29 Nov 2021 $0.06 $0.00 0.00% 278,483 $0.06 $0.06 $0.06
26 Nov 2021 $0.06 $0.00 0.00% 32,928 $0.06 $0.06 $0.06
25 Nov 2021 $0.06 $0.00 0.00% 559,215 $0.06 $0.06 $0.06
24 Nov 2021 $0.06 $0.00 0.00% 470,370 $0.06 $0.06 $0.06
23 Nov 2021 $0.06 $0.00 0.00% 903,939 $0.06 $0.06 $0.06
22 Nov 2021 $0.06 $0.00 0.00% 672,730 $0.06 $0.07 $0.06
19 Nov 2021 $0.06 $0.00 0.00% 287,823 $0.06 $0.06 $0.06
17 Nov 2021 $0.06 $0.00 0.00% 43,656 $0.06 $0.06 $0.06
16 Nov 2021 $0.06 $0.00 0.00% 81,068 $0.06 $0.06 $0.06
15 Nov 2021 $0.06 $0.00 0.00% 1,213,144 $0.06 $0.06 $0.06
12 Nov 2021 $0.06 $0.00 0.00% 723,270 $0.06 $0.06 $0.06
10 Nov 2021 $0.05 $0.00 0.00% 1,265,825 $0.06 $0.06 $0.05
09 Nov 2021 $0.06 $0.00 0.00% 373,066 $0.06 $0.06 $0.06
08 Nov 2021 $0.06 $0.00 0.00% 156,579 $0.06 $0.06 $0.06
05 Nov 2021 $0.06 $0.00 0.00% 712,300 $0.06 $0.06 $0.06
04 Nov 2021 $0.06 $0.00 0.00% 29,446 $0.06 $0.06 $0.06
03 Nov 2021 $0.06 $0.00 0.00% 10,891 $0.06 $0.06 $0.06
02 Nov 2021 $0.06 $0.00 0.00% 198,323 $0.06 $0.06 $0.06

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
18 Jun 2021 Marjan Mikel Buy 517 $36,111
On-market trade.
24 Dec 2020 Thomas (Tom) Duthy Issued 5 $109,596
Director remuneration. Black & Scholes valuation
24 Dec 2020 Marjan Mikel Issued 30 $657,577
Director remuneration. Black & Scholes valuation
24 Dec 2020 Nicholas Smedley Issued 30 $657,577
Director remuneration. Black & Scholes valuation
15 Dec 2020 Marjan Mikel Buy 148 $20,030
On-market trade.
15 Dec 2020 Nicholas Smedley Buy 150 $20,250
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Marjan Mikel Executive DirectorChief Executive OfficerManaging Director Nov 2019
Mr Mikel is a managing director and board Member with a career spanning Australia, Europe and Japan, his focus has been in the healthcare industry from pharmaceuticals and information services and technology to medical devices and sleep disorder solutions. He founded and subsequently sold Healthy Sleep Solutions after has had been develop it into Australia's provider of home based sleep diagnostic and treatment services, with Resmed Ltd as a joint venture/shareholder partner. He has held a number of Board and advisory roles in public and private companies in the areas of healthcare, SaaS and medical devices. He is a former director of Memphasys Ltd.
Dr Thomas (Tom) Duthy Non-Executive Director Feb 2020
Dr Duthy has over 15 years of finance markets experience having worked in sell-side equity research, and executive roles across investor relations and corporate development. Dr Duthy is the Founder and CEO of Nemean Group Pty Ltd, a boutique corporate advisory and investor relations firm specialising in delivering value added services across the life sciences, medical devices, healthcare, technology and emerging companies sectors. Prior, he had spend ten years as a sell-side Healthcare & Biotechnology analyst at Taylor Collison Limited, and has had a focus on companies.
Mr Nicholas Smedley Executive ChairmanExecutive Director Oct 2019
Mr Smedley is an Investment Banker and M&A Advisor, with 14 years experience at UBS and KPMG. He has worked on M&A transactions in the UK, Hong Kong, China, and Australia with transactions ranging from the defence of WMC Resources through to the investment in Catch.com.au. He currently oversees investments in the Property, Aged care, Technology and Medical Technology space. He also has expertise in M&A, Debt structuring, Corporate governance and innovation. He is a director of AD1 Holdings Limited.
Mr Alastair Beard Company Secretary Mar 2019
-
Samaneh Sarraf Shiraz Chief Research Officer
-
Alastair Beard Company Secretary
-
Philippe Ludekens General Manager - Commercial Operations
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Investment Holdings Pty Ltd <Investment Holdings Unit A/C> 72,008,027 11.03%
Netwealth Investments Limited <Wrap Services A/C> 14,841,052 2.27%
Netwealth Investments Limited <Super Services A/C> 14,267,181 2.19%
Mr Peter Karl Braun 13,654,325 2.09%
Mr William John Richards & Mrs Mary Mitchell Richards <Richards Family S/Fund A/C> 9,790,000 1.50%
P & A Mihailou Pty Ltd <Mihailou Family A/C> 8,000,000 1.23%
Hsbc Custody Nominees (Australia) Limited 7,834,313 1.20%
Luhopi Pty Ltd <The Ribot Family Sttlmt A/C> 7,533,614 1.15%
Mr Gary Ronald Heath & Mrs Melissa Louise Heath <G & M Heath Superfund A/C> 7,377,274 1.13%
Dr Belinda Deborah Jackson 7,269,429 1.11%
Coonan Family Superannuation Fund Pty Ltd <Coonan Family S/F A/C> 7,000,000 1.07%
Equitas Nominees Pty Limited <Pb 600812 A/C> 6,642,449 1.02%
Atlantis Investigations Pty Limited <Larayne Porter S/Fund A/C> 6,105,078 0.94%
Mallamanda Pty Ltd <Mallamanda A/C> 6,087,203 0.93%
Mr Ross Spence Baynes 5,500,000 0.84%
More Investment Group Pty Ltd <Bear Superfund A/C> 5,151,818 0.79%
Mrs Mary Mitchell Richards & Ms Kerry Mitchell Mccarthy <Est Eleanor Mary Rylance A/C> 5,050,000 0.77%
Clemwell Pty Ltd <The Wells Family A/C> 5,035,678 0.77%
Dl Marshall Super Pty Ltd <Marshall Super Fund A/C> 4,650,455 0.71%
Oodachi Pty Ltd <P & M Kerr Family A/C> 4,545,455 0.70%

Profile

since

Note